FDA panel backs safety, benefits of Spiriva
WASHINGTON — Federal health experts on Thursday brushed off lingering safety questions about a popular inhaler drug and suggested it carry bolder benefit claims.
The Food and Drug Administration’s panel of lung specialists voted 11-1 in favor of new labeling about the benefits of Boehringer Ingelheim’s Spiriva Handihaler, which is approved to treat lung disease.
The FDA is not required to follow the group’s advice though it usually does.
The German company submitted studies to the FDA showing Spiriva reduces specific side effects of chronic obstructive pulmonary disease, such as coughing, wheezing and shortness of breath.
“I thought both trials showed unequivocal evidence of benefit,” said panelist Daren Knoell, a pharmacy professor at Ohio State University.
Boehringer said in a statement it was pleased with the panel’s vote and would continue working with the FDA as it completes its review. A company spokeswoman declined to disclose the expected date for an FDA decision.
Spiriva is co-marketed in the U.S. by Pfizer Inc., the world’s largest drugmaker.
While Thursday’s meeting was prompted by Boehringer’s request for bolstered labeling claims, FDA regulators also asked the panel to examine conflicting evidence about whether Spiriva increases the risk of heart attack, stroke and death.
An analysis of multiple studies published in the Journal of the American Medical Association last year suggested increased risks with the inhaler. But panelists said a more definitive, 6,000-patient trial by the company did not show increased death, and suggested it can actually reduce that risk.
Panelists voted 11-1 that the company’s data “adequately address” concerns about increased stroke. They voted 11-0, with one abstention, that the same study addresses the issue of increased risk of heart attack.
Panel chair Dr. Mark Brantly said the company might eventually be able to win approval for a claim about the drug’s lifesaving powers.
“We encourage this be pursued as an indication in the future as an important outcome,” said Brantly, a professor of lung care at the University of Florida.
Related News
FDA panel backs stronger benefit claims for inhaler drug Spiriva marketed by PfizerNovember 19th, 2009 FDA panel backs stronger benefits of SpirivaWASHINGTON — Federal health experts say an inhaler drug from a German drugmaker works well enough to carry bolder claims about reducing coughing, wheezing and other respiratory problems. The Food and Drug Administration's panel of lung specialists voted 11-1 to allow Boehringer Ingelheim to add new labeling about the benefits of Spiriva Handihaler, which is approved to treat lung disease.
FDA panel rejects Zimmer spine repair device on questions of safety and effectivenessNovember 4th, 2009 FDA panel rejects Zimmer spine implantGAITHERSBURG, Md. — Federal health advisers on Wednesday rejected an implant from Zimmer Holdings saying it's unclear how effective or safe the device would be for treating a painful spinal condition.
FDA panel questions long-term safety and effectiveness of Zimmer spine repair deviceNovember 4th, 2009 FDA panel has questions about Zimmer spine implantGAITHERSBURG, Md. — Federal health officials say there are lingering questions about whether an implant from Zimmer Holdings Inc.
FDA panel recommends approval of novel heat-based treatment for treating asthmaOctober 28th, 2009 FDA panel backs first non-drug asthma treatmentWASHINGTON — Federal health advisers on Wednesday said a novel technology from a small medical technology firm should be approved as the first non-drug treatment for asthma. The Food and Drug Administration's panel of respiratory device experts voted 6-1 that Asthmatx's Alair System be approved under certain conditions, including long-term safety monitoring of patients.
FDA experts request more data on benefit of Human Genome Sciences' anthrax drugOctober 27th, 2009 FDA panel wants more data on anthrax drugWASHINGTON — Federal advisers said Tuesday that more data is needed to judge the effectiveness of Human Genome Sciences' anthrax treatment compared with existing anti-bacterial drugs. The Food and Drug Administration's panel of infectious disease experts voted 17 to 6, with one abstention, that the company should submit more evidence on whether adding ABthrax to older drugs improves the treatment of anthrax.
Smarter inhaler design allows more efficient drug deliveryOctober 22nd, 2009 WASHINGTON - Smarter inhaler design will enable more effective drug delivery to the lungs by minimising waste. Current designs deliver only 10 to 20 percent of asthma medications to the lungs.
FDA rejects labeling claims on vitamin C-enhanced version of Vicks NyquilOctober 14th, 2009 FDA warns P&G for adding vitamin C to NyquilWASHINGTON — Federal drug regulators are scolding Procter & Gamble for adding Vitamin C to its Vicks cold formulas, a combination not allowed by federal regulations. The Food and Drug Administration issued a warning to the consumer products company, saying medications like Vicks Nyquil and Dayquil have not been approved to contain vitamin C.
FDA panel favors expanded approval for Pfizer HIV drug as an initial treatmentOctober 8th, 2009 FDA panel backs expanded use of Pfizer HIV drugADELPHI, Md. — Federal health advisers said Thursday that Pfizer's HIV drug Selzentry should be approved for use by patients who have not already taken other drugs to combat the virus.
FDA advisers unanimously back GlaxoSmithKline drug for kidney cancer, despite liver risksOctober 5th, 2009 FDA panel unanimously backs Glaxo cancer drugGAITHERSBURG, Md. — Federal health advisers said Monday an experimental kidney cancer drug from GlaxoSmithKline PLC can benefit patients by slowing the disease, despite some risk of liver damage.
FDA panel narrowly backs Schering-Plough's PegIntron as a skin cancer medicationOctober 5th, 2009 FDA panel backs Schering-Plough cancer drugGAITHERSBURG, Md. — Federal health advisers voted 6-4 on Monday that the potential benefits of a Schering-Plough drug outweigh its toxic risks as a treatment for late-stage skin cancer.
FDA panel back approval for abuse-resistant OxyContin pillSeptember 24th, 2009 FDA panel backs reformulated OxyContin pillWASHINGTON — Federal health advisers on Thursday recommended approval for a new version of the painkiller OxyContin that is designed to be harder to abuse. A Food and Drug Administration panel of experts voted 14-4 in favor of the reformulated OxyContin from Purdue Pharma.
FDA says tamper-proof OxyContin provides 'limited' benefit over original painkillerSeptember 22nd, 2009 FDA: 'limited' benefit with tamper-proof OxyContinWASHINGTON — Federal health officials say a new version of the painkiller OxyContin that is designed to be harder to abuse offers some improvements over the original pill. Purdue Pharma LP has touted the new pill's plastic-like coating, which is designed to make the drug harder to crush and snort or inject.
FDA panel says Merck vaccine for cervical cancer Gardasil blocks genital warts in malesSeptember 9th, 2009 FDA panel backs Gardasil for use by menWASHINGTON — Federal health advisers say Merck's vaccine Gardasil, which already is used to prevent cervical cancer in women, should also be approved to stop genital warts in men. A Food and Drug Administration panel voted unanimously with one abstention that the vaccine is effective for blocking the human papilloma virus, or HPV, in males ages 9 to 26.
FDA panel says Allos Therapeutics drug will benefit patients with rare form of lymphomaSeptember 2nd, 2009 FDA panel backs Allos Therapeutics' cancer drugWASHINGTON — Federal health experts voted Wednesday in favor of an experimental cancer drug from Allos Therapeutics for patients with a rare form of cancer. A spokeswoman for the Food and Drug Administration said the agency's panel of oncology experts voted 10-4 that the company's drug pralatrexate would likely benefit patients with T-Cell lymphoma.
FDA panel says Genzyme did not conduct study necessary to prove benefit of leukemia drugSeptember 1st, 2009 FDA panel wants more data on Genzyme cancer drugWASHINGTON — A panel of cancer experts has issued a negative review of a leukemia drug from Genzyme, saying more data is needed to establish its safety and efficacy for older patients. The Food and Drug Administration's oncology panel voted 9-3 Tuesday that Cambridge, Mass.-based Genzyme should be required to conduct a larger, comparison study to prove its drug is safe and effective.
